Glucophage Provision Likely To Remain In Final Pediatric Exclusivity Bill
Executive Summary
The Glucophage provision is likely to be included in the final version of pediatric exclusivity reauthorization legislation with no substantive changes
You may also be interested in...
House Pediatric Exclusivity Bill Passes; CBO Scoring Flawed, Tauzin Says
Thirty to 50 pediatric studies of generic drugs would be funded by the National Institutes of Health over the next five years under HR 2887, House Energy & Commerce Committee Chairman Billy Tauzin (R-La.) estimated
Pediatric Bills' Generic Approval "Carve-Out" Needs Refinement, Hatch Says
Provisions of bills to renew the pediatric exclusivity program which allow for approval of generics despite protected labeling by innovators should be revised, Sen. Orrin Hatch (R-Utah) said.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011